Oct 01, 2026 8:30 am EDT OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Sep 24, 2026 8:22 am EDT OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
Sep 21, 2026 6:30 am EDT OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
Sep 17, 2026 6:00 am EDT OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
Sep 15, 2026 7:46 am EDT OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
Sep 08, 2026 6:00 am EDT OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
Sep 02, 2026 7:20 am EDT OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
Aug 17, 2026 7:40 am EDT OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Aug 13, 2026 8:45 am EDT OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Jul 08, 2026 9:00 am EDT OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program